FirstTake on Pharma - Pharma News and Analysis Podcast podkast

The FirstTake Podcast – A landmark cancer approval, Pfizer’s Arena deal delivers and the expert view on recent breast cancer developments

Do tyłu o 15 sekund
Do przodu o 15 sekund
On this week’s episode editors Virginia Li and Simon King discuss FDA approval of the first novel checkpoint inhibitor for eight years – Bristol Myers Squibb’s LAG-3 inhibitor relatlimab – and evaluate positive data for Pfizer’s etrasimod, which it gained via December’s $6.7 billion acquisition of Arena Pharmaceuticals. In addition, FirstWord’s Michael Flanagan speaks to Adam Brufsky – professor of medicine at the University of Pittsburgh School of Medicine and associate chief for the school’s haematology/oncology division – to discuss the relevance of recent clinical and regulatory events that will impact the treatment of breast cancer.

Więcej odcinków z kanału "FirstTake on Pharma - Pharma News and Analysis Podcast"